LASER-ASSISTED TREATMENT OF ORAL MUCOSAL DISEASES IN PATIENTS WITH CHRONIC RENAL FAILURE: CLINICAL OUTCOMES AND EVIDENCE-BASED RECOMMENDATIONS

Oral mucosal diseases are prevalent among patients with chronic kidney disease (CKD) and are often complicated by oxidative stress and immune dysregulation. This study evaluates the clinical outcomes of integrating low-level laser blood irradiation (LLLI) with conventional antiseptic therapy in the management of oral inflammatory conditions in CKD patients. The prospective controlled trial included 100 CKD patients with chronic inflammatory oral lesions, divided into a control group receiving standard antiseptic therapy and a main group additionally treated with LLLI and immunomodulatory antiseptics. Clinical assessments, along with biochemical and immunological parameters, were used to evaluate treatment efficacy. The results demonstrated superior outcomes in the LLLI group, including improved epithelial healing, reduced recurrence, and enhanced biochemical markers, supporting the integration of LLLI into standard care protocols.